pH-Sensitive Nanoparticles for Retinal Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene delivery systems for treating visual disorders face challenges with low transfection efficiency and lack of specificity, leading to potential disorders due to unintended tissue targeting in the eye, which requires high specificity and efficiency for effective gene therapy.
Innovation Solution
Development of multifunctional pH-sensitive carriers or nanoparticles that condense therapeutic nucleic acids, featuring a protonable amino head group, cysteine residues for disulfide bridge formation, and a targeting group that binds to retinal or visual proteins, enhancing delivery specificity and efficiency to the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-viral delivery systems are used, then safety and ease of production are improved, but transfection efficiency is reduced
Solution Approach 1:
The patent employs composite materials by combining cationic lipids with cell-penetrating peptides and targeting ligands to create multifunctional delivery vectors. This composite approach integrates the safety advantages of non-viral systems with enhanced transfection efficiency through the synergistic properties of different material components.
Solution Approach 2:
The patent utilizes parameter changes by adjusting the physical and chemical properties of the delivery vectors, including lipid composition, peptide sequences, and nanoparticle size. These parameter optimizations enable the system to achieve high transfection efficiency while maintaining the safety profile of non-viral approaches.
2Ease of manufacture
If non-viral delivery systems are used, then ease of production is improved, but transfection efficiency is reduced
Solution Approach 1:
The patent applies segmentation by dividing the delivery system into modular components: lipid formulations, peptide sequences, and targeting ligands. This modular design simplifies production processes while enabling systematic optimization of transfection efficiency through independent development and combination of each component.
Solution Approach 2:
The patent employs parameter changes by systematically optimizing physical and chemical characteristics of each module, including lipid chain length, peptide charge density, and ligand binding affinity. These parameter adjustments facilitate ease of production while achieving high transfection efficiency.
3Ease of operation
If gene therapy is applied to the eye, then accessibility and immune-privileged characteristics are improved, but specificity is reduced
Solution Approach 1:
The patent implements local quality by incorporating tissue-specific targeting ligands that confer selective binding properties to the delivery vectors. This enables the system to exploit the accessibility of the eye while achieving high specificity for retinal cells through localized molecular recognition at the target site.
Solution Approach 2:
The patent uses intermediary molecules, specifically targeting ligands such as RPE65-specific antibodies or peptides, that act as mediators between the delivery vector and retinal cells. These intermediaries enable precise targeting within the accessible ocular environment, ensuring specificity despite the ease of access.
4Reliability
If gene therapy is applied to the eye, then immune-privileged characteristics are improved, but transfection efficiency is reduced
Solution Approach 1:
The patent employs composite materials by formulating delivery vectors that combine biocompatible lipids with cell-penetrating peptides and targeting ligands. This composite structure exploits the immune-privileged status of the eye while achieving high transfection efficiency through the synergistic properties of multiple material components.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the physical and chemical properties of the delivery vectors, including surface charge, size, and composition. These parameter adjustments enable efficient transfection within the immune-privileged ocular environment while maintaining low immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described nanoparticles demonstrate improved transfection efficiency and specificity, effectively delivering therapeutic nucleic acids to the retina, as shown by enhanced GFP expression and functional restoration in animal models, with evidence of sustained therapeutic effects and safety.
Implementation Method 1
The compounds can include a protonable amino head group, which can complex with the nucleic acids
Implementation Method 2
fatty acid or lipid tails, which can participate in hydrophobic condensation
Implementation Method 3
two cysteine residues capable of forming disulfide bridges via autooxidation
Implementation Method 4
a targeting group that targets and/or binds to a retinal or visual protein, such as an interphotoreceptor retinoid binding protein
Data Source
AI summary
A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or includes a polymer, a targeting group, or a detectable moiety, and at least one of R4 and R5 includes a targeting group that targets and/or binds to a retinal or visual protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.